Inactive Instrument

Neurotrope, Inc.

Equities

NTRP

US64129T2078

Neurotrope, Inc Appoints Susanne Wilke as Chief Executive Officer

September 06, 2016 at 08:30 am EDT

Neurotrope, Inc. announced that it has appointed Dr. Susanne Wilke, PhD as Chief Executive Officer. Dr. Wilke brings significant leadership, sector and investing experience to Neurotrope based upon her work at leading biotechnology and pharmaceutical companies including Hoffman La Roche, Amgen, and Forest Labs. Dr. Wilke also served as a Kaufman Fellow at Schroder Ventures Life Sciences, a leading international Venture Capital Firm, and was an Investment Principal at NGN Capital.

Latest news about Neurotrope, Inc.

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.	20-12-01	CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.	20-11-30	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease	20-10-06	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-12	CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1	20-06-10	CI
Neurotrope, Inc. Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease	20-05-28	CI
Metuchen Pharmaceuticals LLC entered into a non-binding term sheet to acquire Neurotrope, Inc. from Intracoastal Capital LLC and others for approximately $140 million in a reverse merger transaction.	20-05-17	CI
Neurotrope, Inc. intends to spin off Neurotrope Bioscience, Inc.	20-05-16	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-13	CI
Neurotrope, Inc. Announces Board Resignations	20-02-27	CI
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial	20-01-22	CI
National Institute of Health Awards $2.7 Million Grant to Neurotrope	20-01-22	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Neurotrope Reviews Strategic Alternatives to Maximize Shareholder Value	19-10-08	CI
Neurotrope, Inc. Announces Top-Line Results from Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	19-09-09	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease	19-07-15	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-09	CI
Neurotrope, Inc. Appoints Michael Ciraolo as General Counsel and Chief Operating Officer	19-04-01	CI
Neurotrope Inc Comments on Biogen's Discontinued Phase 3 Trial in Alzheimer's Disease	19-03-21	CI
Neurotrope Inc. Completes Enrollment of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	19-03-13	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-08	CI
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute	19-02-04	CI

Chart Neurotrope, Inc.

Duration

Period

More charts

Company Profile

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.

Sector

More about the company